ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation

Science

Volumn 328, Issue 5986, 2010, Pages 1689-1693

  Yvan Charvet, Laurent ^a   Pagler, Tamara ^a   Gautier, Emmanuel L ^b   Avagyan, Serine ^b   Siry, Read L ^a   Han, Seongah ^a   Welch, Carrie L ^a   Wang, Nan ^a   Randolph, Gwendalyn J ^b   Snoeck, Hans W ^b   Tall, Alan R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

BIOCHEMISTRY; BLOOD SYSTEM DISORDER; CYTOLOGY; DISEASE INCIDENCE; GENETICALLY MODIFIED ORGANISM; PROTEIN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HYPERCHOLESTEROLEMIA; LEUKOCYTE; LEUKOCYTOSIS; MONOCYTE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; STEM CELL EXPANSION;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; HEMATOPOIETIC STEM CELLS; HYPERCHOLESTEROLEMIA; LEUKOCYTOSIS; LIPOPROTEINS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MULTIPOTENT STEM CELLS; MYELOID PROGENITOR CELLS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, INTERLEUKIN-3; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 77954039619     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1189731     Document Type: Article

References (32)

1. B. S. Coller, Arterioscler. Thromb. Vase. Biol. 25, 658 (2005).
2. D. J. Gordon, B. M. Rifkind, N. Engl. J. Med. 321, 1311 (1989).
3. P. J. Barter, R. Puranik, K. A. Rye, Curr. Cardiol. Rep. 9, 493 (2007).
4. A. R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, N. Wang, Cell Metab. 7, 365 (2008).
5. D. Duffy, D. J. Rader, Nat. Rev. Cardiol. 6, 455 (2009).
6. L. Yvan-Charvet et al., J. Clin. Invest. 117, 3900 (2007).
7. X. Wang et al., J. Clin. Invest. 117, 2216 (2007).
8. R. Out et al., Arterioscler. Thromb. Vase. Biol. 28, 258 (2008).
9. R. Out et al., Cire. Res. 102, 113 (2008).
10. L. Yvan-Charvet et al., Circulation 118, 1837 (2008).
11. Materials and methods are available as supporting material on Science Online.
12. E. E. Turer et al., J. Exp. Med. 205, 451 (2008).
13. S. D. Peeters et al., Exp. Hematol. 34, 622 (2006).
14. E. P. de Grouw et al., Leukemia 20, 750 (2006).
15. I. L. Weissman, J. A. Shizuru, Blood 112, 3543 (2008).
16. A. Wilson et al., Cell 135, 1118 (2008).
17. M. P. Adorni et al., J. Lipid Res. 48, 2453 (2007).
18. S. J. Bensinger et al., Cell 134, 97 (2008).
19. B. L. Wagner et al., Mol. Cell. Biol. 23, 5780 (2003).
20. E. M. Rubin, R. M. Krauss, E. A. Spangler, J. G. Verstuyft, S. M. Clift, Nature 353, 265 (1991).
21. A. S. Plump, C. J. Scott, J. L. Breslow, Proc. Natl. Acad. Sci. U.S.A. 91, 9607 (1994).
22. C. Dietrich, Z. N. Volovyk, M. Levi, N. L. Thompson, K. Jacobson, Proc. Natl. Acad. Sci. U.S.A. 98, 10642 (2001).
23. B. J. Nichols, Curr. Biol. 13, 686 (2003).
24. F. Chang et al., Leukemia 17, 1263 (2003).
25. U. Testa et al., Leukemia 18, 219 (2004).
26. F. Geissmann et al., Science 327, 656 (2010).
27. L. E. Averill, R. C. Meagher, R. G. Gerrity, Am. J. Pathol. 135, 369 (1989).
28. F. K. Swirski et al., Proc. Natl. Acad. Sci. U.S.A. 103, 10340 (2006).
29. F. K. Swirski et al., J. Clin. Invest. 117, 195 (2007).
30. F. Tacke et al., J. Clin. Invest. 117, 185 (2007).
31. C. Combadière et al., Circulation 117, 1649 (2008).
32. This work is supported by a Program Project grant from the NIH to A.R.T. (HL54591) and a grant from the American Heart Association to L.Y.-C. (SDG2160053), by the FWF Austrian Science Fund (T.P.), and by NIH grants R01A1061741 (E.L.G. and G.J.R.) and R01AG016327 (H.W.S.). A.R.T. serves on scientific advisory boards for Merck and Arisaph Pharmaceuticals and provides paid consulting services to Roche, Merck, Arisaph Pharmaceuticals, and CSL Limited related to the development of drugs that would increase HDL levels.